September 19, 2018

IAVI and our partners head to Madrid on Oct. 21 to 25 for the 2018 HIV Research for Prevention conference.

HIVR4P 2018 Logo Formats v2 CMYK 02

Despite remarkable advances in treatment and prevention, HIV/AIDS is neither contained nor manageable. In 2017, 36.9 million people globally were living with HIV, 1.8 million were newly infected, and AIDS-related illnesses killed more 940,000 people. Access and adherence to available prevention and treatment remain challenging for many. Innovation in HIV prevention and a vaccine are needed to end AIDS.

The HIV Research for Prevention conference (HIVR4P 2018), from Oct. 21 to 25 in Madrid, will gather 1,500 leaders in HIV prevention research, programs, and policy to share the latest progress and look at future steps. HIVR4P 2018 is the world’s only scientific meeting dedicated exclusively to biomedical HIV prevention research.



Click session titles for full details

Sunday, Oct. 21: Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention

Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention

Time: 15:00-18:00
Location: Marsella Room
Co-chairs: Kenneth H. Mayer, Harvard Medical School, U.S.; Sylvia Adebajo, Population Council, Nigeria
Speaker: Anatoli Kamali, IAVI, East Africa
Hosts: IAVI; U.S. Military HIV Research Program

The purpose of this meeting is to convene researchers and other stakeholders to discuss how African MSM can be successfully engaged in planned HIV biomedical prevention trials, discuss various recruitment and retention strategies from Africa, and develop best practices and tools to inform future research in Africa and other regions.

  1. Overview: HIV Prevalence, HIV Incidence, and Retention from Key African Studies of MSM – Joshua Kimani, University of Manitoba Kenya office

  2. Plenary: Including African MSM in HIV biomedical prevention research – opportunities, challenges – Anatoli Kamali, IAVI

  3. Lessons learned in recruitment and retention of African MSM

    • Frederick Otieno, Nyanza Reproductive Health Society

    • Elizabeth Wahome, Kenya Medical Research Institute

    • Trevor Crowell, U.S. Military HIV Research Program-Nigeria

    • Jauhara Nanyondo, Makerere University Walter Reed Project

    • Victor Akelo, Kenya Medical Research Institute/CDC

    • Travis Sanchez, Emory University

  4. Strategic community engagement

    • Kenedy Abor Owiti, NYARWEK Network

    • Sylvia Adebajo, Population Council, Nigeria

  5. Moderated Panel Q & A Discussion

  6. Closing remarks – Merlin Robb, U.S. Military HIV Research Program

Monday, Oct. 22: Catalyzing Translational Research to Advance HIV Vaccine and Immune-based Cure Research in Africa

Catalyzing Translational Research to Advance HIV Vaccine and Immune-based Cure Research in Africa: Cross-cutting Translational Research and Capacity Strengthening in Africa

Time: 08:30-11:30
Location: Dresden & Stuttgart Room
Co-chairs: Daniel Ochiel, IAVI, Kenya; Thumbi Ndung'u, University of KwaZulu-Natal, South Africa
Margaret McCluskey, Senior Technical Advisor, HIV Vaccines, USAID Office of HIV/AIDS; Benny Kottiri, Research Division Chief, USAID Office of HIV/AIDS
Presenter: Roger Tatoud, IAVI, U.K., IAVI DataSpace
Hosts: IAVI; University of KwaZulu-Natal

This satellite will showcase early and mid-level career African scientists supported by a 15-year IAVI-led USAID-funded capacity program and from the SANTHE consortium, part of the DELTAS Africa Initiative, an independent funding scheme of the African Academy of Sciences’ (AAS's) Alliance for Accelerating Excellence in Science in Africa (AESA). This satellite workshop will aim to provide evidence of the impact that these investments have created in translational biomedical research in Africa. This session will also host a moderated panel discussion by African investigators to share personal career pathways, experiences and perspectives on how research capacity and research outputs could be further strengthened and improved on the continent.

Monday, Oct. 22: Voices in the Long-acting PrEP Movement

Voices in the Long-acting PrEP Movement: Fostering Dialog Between End-users and Product Developers During the Product Development Process

Time: 08:30-11:30
Location: Burdeos Room
Co-chairs: Linda-Gail Bekker, Desmond Tutu HIV Centre, University of Cape Town, South Africa; Mitchell Warren, AVAC, U.S.
Maggie Keane, IAVI
RTI International; Desmond Tutu HIV Research Foundation; AVAC; IAVI

This satellite session aims to demonstrate and discuss strategies to foster open and iterative dialog between end-users and product developers of long-acting HIV prevention products. The objective of hosting this satellite is directly in line with the theme of this year’s HIVR4P Conference, From Research to Impact. Satellite presenters, those working both in product development and those interfacing with target populations of young women in Southern Africa, aim to achieve synergistic solutions for the development of long-acting HIV PrEP products that are safe, effective, acceptable and appropriate for their target end-users, a goal that will ultimately achieve the greatest public health impact.

Monday, Oct. 22: Human Centric Vaccine Discovery

Human Centric Vaccine Discovery

Time: 12:00-15:00
Location: Marsella Room
Chair: Robin Shattock, Imperial College, United Kingdom
Mark Feinberg, IAVI

This session will highlight the importance of discovery-phase clinical vaccine trials.


Wednesday, Oct. 24: Accelerating Product Introduction for Impact

Accelerating Product Introduction for Impact

Location: Bristol Room
Chairs: Nyaradzo Mgodi, University of Zimbabwe Collaborative Research Program; Mitchell Warren, AVAC, U.S.

Millions of new HIV infections occur yearly despite availability of novel and effective HIV prevention products. This session will explore best practices for prevention product introduction and discuss successes as well as challenges using lessons learnt from completed demonstration projects. Best practices from sexual and reproductive health technologies and experiences from non-HIV vaccines will be used as examples of implementation planning for product introduction.


15:00-15:10: RT01.01 – Preparing for Successful Implementation of Prevention Strategies, Hasina Subedar, Department of Health, South Africa

15:10-15:20: RT01.02 – Learning From the Past: Planning for Future Success in Implementing Biomedical HIV Prevention Products, Alex Coutinho, Partners in Health, Rwanda

15:20-15:30: RT01.03 – Successes and Shortcomings in Introducing Sexual and Reproductive Health Technologies: Insights From End-users, Providers and Policy Makers, Martha Brady, PATH, U.S.

15:30-15:40: RT01.04 – Learning from History: Roll-out of Non-HIV Vaccines, Mark Feinberg, IAVI

15:40-15:50: RT01.05 – Introduction of New Health Technologies in HIV Prevention and Treatment Trials: Best Practices of Community Engagements and Communication in Peru, Maria del Rosario Leon, Impacta Salud y Educacion, Peru

15:50-16:30: Panel Discussion


Tuesday, Oct. 23: Structure and Maturation of bNAbs

Presentation: Fast and Focused Maturation of VH1-2-Restricted HIV-Env CD4-Binding Site Targeting bNAbs
Speaker: Elise Landais
Location: Oxford Room

Tuesday, Oct. 23: Understanding Protection Against HIV From the T Cell Perspective

Presentation: Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth of HIV in the Context of a CD8 T-Cell Mediated HIV Response
Speaker: Jonathan Hare
13:00 - 14:30
Location: Oxford Room

Tuesday, Oct. 23: Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials

Presentation: Community Engagement in the Design and Implementation of HIV Prevention Trials: Uganda Virus Research Institute-International AIDS Vaccine Initiative
Speaker: Gertrude Nanyonjo
Location: Oxford Room

Tuesday, Oct. 23: Revealing Targets for Prevention and Cure

Presentation: Transmitted/Founder Virus-Like Variants are Archived in the Reservoir
Speaker: Kelsie Brooks
Location: Londres Room

Wednesday, Oct. 24: Novel Vaccine Strategies

Presentation: Vaccine-Elicited Cross-Neutralizing HIV Antibodies (bNAbs) to Two Env Sites of Vulnerability Following Heterologous NFL Trimer Liposome Prime:Boosting
Speaker: Richard Wyatt
Location: Oxford Room

Wednesday, Oct. 24: Mechanisms of Natural Control

Presentation: Heightened Inflammatory Response to Acute HIV-1 Infection in Zambian Women Compared to Men
Speaker: Elina El-Badry
Location: Londres Room

Thursday, Oct. 25: Factors Influencing Viral Transmission and Spread

Presentation: HLA Pre-Adaption in Gag Influences Viral Evolution in the New Host
Speaker: Daniela Monaco
Location: Bristol Room

Thursday, Oct. 25: Factors Influencing Viral Transmission and Spread

Presentation: Infection with Multiple Transmitted/Founder (T/F) Viruses Drives HIV-1 Pathogenesis
Speaker: Gladys Macharia
Location: Bristol Room

Thursday, Oct. 25: Opinion 360: Meaningful Engagement from Research to Roll Out

Co-chairs: Manju Chatani-Gada, AVAC and Kundai Chinyenze, IAVI
Location: Oxford Room


Media Contacts


Ethel Makila
+254 71 904 3142 



Hester Kuipers
+31 20 521 0343 



Saif ul Hadi
+91 11 4737 6032 


North America

Rose Catlos
+1 212 847 1049